 |
|
A Controlled Study of the Antidepressant Efficacy and Side Effects of ( — )-DeprenylA Selective Monoamine Oxidase Inhibitor
J. John Mann, MD;
Shelley Fox Aarons, MD;
Philip J. Wilner, MD;
John G. Keilp, MA;
John A. Sweeney, PhD;
Teri Pearlstein, MD;
Allen J. Frances, MD;
James H. Kocsis, MD;
Richard P. Brown, MD
Arch Gen Psychiatry. 1989;46(1):45-50.
Abstract
| |
• Monoamine oxidase (MAO) inhibitors are effective antidepressants whose use is limited because of unwanted side effects and the possibility of a tyramine-induced hypertensive crisis (cheese reaction). ( - )-Deprenyl (the official nonproprietary name for this substance is selegiline), a selective MAO type B inhibitor, may be safer and have fewer side effects, but its antidepressant efficacy is uncertain. A double-blind placebo-controlled study was carried out in depressed outpatients who were treated with ( - )-deprenyl in an MAO type B selective dose range and at a higher nonselective dose range. (-)-Deprenyl did not have a statistically significant antidepressant effect after three weeks of treatment at doses of 10 mg/d. However, after six weeks and at higher doses (averaging about 30 mg/d for the second three weeks), ( - )-deprenyl was superior to placebo in antidepressant effect with a positive response rate of 50% vs 13.6% and with a 41% reduction in the Hamilton Depression Rating Scale mean score vs 10% in the placebo-treated group. No hypertensive crises were seen. The rate of occurrence of side effects with (-)-deprenyl was no greater than with placebo. It was concluded that (-)-deprenyl is an effective antidepressant in a dose range where it is distinguished by the absence of many of the side effects typical of nonselective MAO inhibitors.
Author Affiliations
From the Laboratory of Psychopharmacology, Department of Psychiatry, Cornell University Medical College, New York. Dr Pearlstein is now with the University of Pittsburgh School of Medicine, and Dr Brown is now with The New York State Psychiatric Institute, New York.
Footnotes
Accepted for publication Jan 15, 1988.
Reprint requests to the Laboratory of Psychopharmacology, Department of Psychiatry, Cornell University Medical College, 1300 York Ave, New York, NY 10021 (Dr Mann).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Pharmacokinetics and Absolute Bioavailability of Selegiline Following Treatment of Healthy Subjects With the Selegiline Transdermal System (6 mg/24 h): A Comparison With Oral Selegiline Capsules
Azzaro et al.
J Clin Pharmacol 2007;47:1256-1267.
ABSTRACT
| FULL TEXT
Tyramine Pressor Sensitivity During Treatment With the Selegiline Transdermal System 6 mg/24 h in Healthy Subjects.
Azzaro et al.
J Clin Pharmacol 2006;46:933-944.
ABSTRACT
| FULL TEXT
A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease
Youdim and Riederer
Neurology 2004;63:S32-S35.
FULL TEXT
Transdermal Selegiline in Major Depression: A Double-Blind, Placebo-Controlled, Parallel-Group Study in Outpatients
Bodkin and Amsterdam
Am. J. Psychiatry 2002;159:1869-1875.
ABSTRACT
| FULL TEXT
Depression and epilepsy: How closely related are they?
Kanner and Balabanov
Neurology 2002;58:S27-39.
ABSTRACT
| FULL TEXT
The Depressions of Alzheimer's Disease: Sorting, Pharmacotherapy, and Clinical Advice
Knesper
J Geriatr Psychiatry Neurol 1995;8:S40-S51.
ABSTRACT
High-Dose Selegiline in Treatment-Resistant Older Depressive Patients
Sunderland et al.
Arch Gen Psychiatry 1994;51:607-615.
ABSTRACT
{blacktriangledown}Moclobemide for depression
DTB 1994;32:6-8.
ABSTRACT
| FULL TEXT
The effect of deprenyl (selegiline) on the natural history of Parkinson's disease
Tetrud and Langston
Science 1989;245:519-522.
ABSTRACT
Psychiatry
Glass and Freedman
JAMA 1989;261:2883-2885.
ABSTRACT
|
